773140-42-4

Upstream product

• 93777-26-5 5-bromo-2-fluorobenzaldehyde 
• 146328-85-0 5-bromo-2-fluoro-benzoic acid 

Downstream Products

• 552331-21-2 (5-bromo-2-fluorophenyl)(1H-pyrrol-2-yl)methanone 
• 936565-01-4 3-[bis-(5-bromo-2-fluoro-benzoyl)-amino]-pyrazine-2-carboxylic acid ethyl ester 
• 214210-17-0 5-bromo-2-fluorobenzamide 
• 1070400-13-3 5-bromo-2-fluoro-N-(2-hydroxy-1,1-dimethylethyl)benzamide 
• 1055880-49-3 N-benzyl-5-bromo-2-fluoro-N-(2-hydroxyethyl)benzamide 
• 1094251-44-1 (5-bromo-2-fluorophenyl)-(4-methoxyphenyl)-methanone 
• 949443-48-5 2-bromo-5-fluoro-N-phenylbenzamide 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS MTOR INHIBITORS

The present disclosure describes novel heterocyclic mTOR inhibitors and methods for preparing them. The pharmaceutical compositions comprising such mTOR inhibitors and methods of using them for treating cancer, infectious diseases, and other mTOR associated disorders are also described.

Preparation method of 5-bromo-2-methyl-3-isopropyl-indazole

The invention discloses a preparation method of 5-bromo-2-methyl-3-isopropyl-indazole. The preparation method of the 5-bromo-2-methyl-3-isopropyl-indazole comprises the following steps: reacting a compound I with an acylating chlorination reagent to gener

Preparation method of fluzoparib

The invention discloses a preparation method of fluzoparib, and belongs to the technical field of chemical synthesis of medicines. The preparation method comprises the following steps: carrying out acylating chlorination reaction on 5-bromo-2-fluorobenzoi

Glucopyranosyl derivative and its use in medicine (by machine translation)

The invention relates to a as sodium-dependent glucose transporter (SGLTs) inhibitors of the glucopyranosyl derivative, containing the pharmaceutical composition and its use in medicine, in particular of formula (I) indicated by the glucopyranosyl derivative or its pharmaceutically acceptable salt or all of its stereoisomers, or containing the pharmaceutical composition and said derivative and pharmaceutical composition for the preparation of a medicine for treating diabetes and diabetes related diseases of the use. (by machine translation)

IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER

The specification generally relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, where x, R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.

IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER

The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where R1 is tetrahydropyran-3-yl or 3,3-dimethyltetrahydropyran-4-yl; R2 is methyl or hydro; R3 is hydro or fl

8-[6-[3-(AMINO)PROPOXY]-3-PYRIDYL]-1 -ISOPROPYL-IMIDAZO[4,5-C]QUINOLIN-2-ONE DERIVATIVES AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE FOR THE TREATMENT OF CANCER

The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where Rl, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also discloses the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.

IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER

The specification generally relates to compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, where R1, R2, R3 and R4 have any of the meanings defined herein. The specification also relates

IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER

The specification generally relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, where R1 is 4-fluoropiperidin-1-yl or 3-fluoropyrrolidin-1-yl and R2 is methyl or hydro; the use of compounds of Formula (I) or pharmaceutically acceptable salts thereof to treat or prevent ATM mediated disease, including cancer; pharmaceutical compositions comprising substituted imidazo[4,5- c]quinolin-2-one compounds or pharmaceutically acceptable salts thereof; kits comprising compounds of Formula (I) or pharmaceutically acceptable salts thereof; methods of manufacture of compounds of Formula (I) or pharmaceutically acceptable salts thereof; and intermediates useful in such manufacture.

Metal-Free Synthesis of Dibenzoxazepinones via a One-Pot SNAr and Smiles Rearrangement Process: Orthogonality with Copper-Catalyzed Cyclizations

Reported is the transition-metal-free synthesis of substituted dibenzoxazepinones using a convergent domino SNAr-Smiles rearrangement-SNAr process. Substrate-scope investigations demonstrated the critical importance of ring electroni